Loading stock data…
BIVI
$1.68+0.03 (+1.82%)
Market ClosedLast close May 1
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
BioVie Inc. in the Healthcare sector is trading at $1.68. The stock is currently near its 52-week low of $1.06, remaining 12.5% below its 200-day moving average. Technical signals show overbought RSI of 71 and bullish MACD crossover, explaining why BIVI maintains its current current market pressure. The Whystock Score of 0/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 71) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.68
Potential Upside
5%
Whystock Fair Value$1.76
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$11.76M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.56
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-90.50%
Volume
Today's trading volume
177,298
Recent News
BioVie abstract on Parkinson’s drug accepted for neurology conference
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said on Tuesday an abstract from its mid-stage study of experimental Parkinson’s disease treatment bezisterim has been accepted for presentation at an upcoming neurology conference. The abstract, based on the company’s SUNRISE-PD trial evaluating...
BioVie CEO explains Bezisterim Parkinson’s trial results - ICYMI
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) earlier this week outlined its evolving approach to Parkinson’s disease, with CEO Cuong Do highlighting the company’s focus on neuroinflammation and insulin resistance as key drivers of the condition. Speaking to Proactive, Do explained that while...
BioVie targets neuroinflammation and insulin resistance in Parkinson’s treatment approach
BioVie CEO Cuong Do joined Steve Darling from Proactive to discuss the company’s novel approach to treating Parkinson’s disease, focusing on neuroinflammation and insulin resistance as key drivers of the condition. Do challenged the traditional view of Parkinson’s as solely a dopamine-related disorder, explaining that inflammation in the brain may play a more fundamental role. He noted that insulin resistance can impair the ability of brain cells to access glucose, stating, “If you have inflammation, the inflammation acts like rust on that lock… and therefore the door stays closed and glucose cannot get in.” This lack of energy in neurons may contribute significantly to disease progression. BioVie’s lead drug candidate, Bezisterim, is designed to target these underlying mechanisms. According to Do, clinical trials have shown that patients receiving the therapy experienced reductions in neuroinflammation along with improvements in insulin sensitivity. Earlier studies combining Bezisterim with Levodopa also demonstrated enhanced muscle control compared to standard treatment alone. The company is now advancing a new clinical trial evaluating Bezisterim as a standalone therapy in early-stage Parkinson’s patients. The study is designed to assess both motor and non-motor symptoms, including sleep, anxiety, and depression. With enrollment now complete, BioVie is targeting a topline data readout before the end of June, marking an important near-term catalyst for the program. proactiveinvestors #biovieince #nasdaq #bivi #NeurodegenerativeDiseases #parkinsonsdisease #BrainHealth #BioVie #CognitionImprovement #Neuroinflammation #SocialImpact #ElderlyCare #Neuroscience #HealthCrisis #DementiaSupport #BrainScience #GlobalHealth #InsulinResistance #Biotech #DrugDevelopment #ClinicalTrials #Bezisterim #CNSResearch #Neuroscience #HealthcareInnovation #MedicalResearch #Biopharma #Neurodegeneration #ToplineData
BioVie targets Parkinson’s at its source with lead drug bezisterim
For decades, treatment of Parkinson’s disease has centered on replacing dopamine, the neurotransmitter whose decline drives the disease’s hallmark motor symptoms. But while therapies such as levodopa can temporarily restore movement, they do little to address the underlying neurodegeneration,...
BioVie to present Parkinson’s study data at AD/PD 2026 conference
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) announced that an abstract from its SUNRISE-PD study evaluating its lead candidate bezisterim (NE3107) for Parkinson’s disease has been accepted for presentation at the AD/PD 2026 Advances in Science & Therapy annual meeting. The conference is...